ATE488600T1 - Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion - Google Patents

Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion

Info

Publication number: ATE488600T1
Authority: AT; Austria
Prior art keywords: galactose; culture; sialylation; cell culture; methods
Prior art date: 2002-12-23

Application number

AT03808535T

Other languages

English (en)

Inventor

Bernhard Schilling

Scott Gangloff

Dharti Kothari

Kirk Leister

Linda Matlock

Stephen Zegarelli

Christoph Joosten

Jonathan Basch

Sivakesava Sakhamuri

Steven Lee

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2003-12-18

Publication date

2010-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE488600(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-12-18 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE488600T1 publication Critical patent/ATE488600T1/de

Links

238000000034 method Methods 0.000 title abstract 6
238000004113 cell culture Methods 0.000 title abstract 5
230000014616 translation Effects 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title 1
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 abstract 8
230000009450 sialylation Effects 0.000 abstract 4
238000012258 culturing Methods 0.000 abstract 3
239000012526 feed medium Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000003886 Glycoproteins Human genes 0.000 abstract 1
108090000288 Glycoproteins Proteins 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000003833 cell viability Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007423 decrease Effects 0.000 abstract 1
230000003111 delayed effect Effects 0.000 abstract 1
229930182830 galactose Natural products 0.000 abstract 1
238000011081 inoculation Methods 0.000 abstract 1
210000004962 mammalian cell Anatomy 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000013341 scale-up Methods 0.000 abstract 1
230000009469 supplementation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT03808535T 2002-12-23 2003-12-18 Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion ATE488600T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43605002P	2002-12-23	2002-12-23
PCT/US2003/040939 WO2004058944A2 (en)	2002-12-23	2003-12-18	Product quality enhancement in mammalian cell culture processes for protein production

Publications (1)

Publication Number	Publication Date
ATE488600T1 true ATE488600T1 (de)	2010-12-15

Family

ID=32682324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03808535T ATE488600T1 (de)	2002-12-23	2003-12-18	Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion

Country Status (21)

Country	Link
US (2)	US7332303B2 (de)
EP (1)	EP1576182B2 (de)
JP (1)	JP4496086B2 (de)
KR (1)	KR101088223B1 (de)
CN (1)	CN100402660C (de)
AT (1)	ATE488600T1 (de)
AU (1)	AU2003303394B2 (de)
BR (1)	BR0316882A (de)
CA (1)	CA2508925C (de)
CO (1)	CO5590971A2 (de)
CY (1)	CY1111358T1 (de)
DE (1)	DE60335024D1 (de)
DK (1)	DK1576182T4 (de)
ES (1)	ES2354610T5 (de)
IL (1)	IL168873A (de)
MX (1)	MXPA05006522A (de)
PL (1)	PL377603A1 (de)
PT (1)	PT1576182E (de)
SI (1)	SI1576182T2 (de)
TW (1)	TWI328614B (de)
WO (1)	WO2004058944A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en)	1991-06-27	2005-05-03	Bristol-Myers Squibb Company	Method to inhibit T cell interactions with soluble B7
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7304033B2 (en)	2001-05-23	2007-12-04	Bristol-Myers Squibb Company	Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
MXPA05006522A (es) *	2002-12-23	2006-02-17	Bristol Myers Squibb Co	Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
TWI312368B (en) *	2002-12-23	2009-07-21	Bristol Myers Squibb Compan	Mammalian cell culture processes for protein production
EA008670B1 (ru) *	2003-05-09	2007-06-29	Круселл Холланд Б.В.	Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
US7754209B2 (en) *	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
KR20090087514A (ko)	2003-08-04	2009-08-17	브리스톨-마이어스 스큅 컴퍼니	가용성 ｃｔｌａ4 돌연변이체 분자를 사용한 심혈관 질환의 치료 방법
US7815765B2 (en) *	2004-04-01	2010-10-19	Swei Mu Wang	Method for forming laminated synthetic leather
ME02930B (me)	2005-04-06	2018-04-20	Bristol Myers Squibb Co	Metode za lečenje imunskih poremećaja povezanih sa transplantacijom grafta sa solubilnim ctla4 mutantnim molekulima
SG155912A1 (en)	2005-07-25	2009-10-29	Trubion Pharmaceuticals Inc	B-cell reduction using cd37-specific and cd20-specific binding molecules
US8470318B2 (en)	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969007B1 (de) *	2005-12-20	2013-08-28	Bristol-Myers Squibb Company	Zusammensetzungen und verfahren zur herstellung einer zusammensetzung
US9309316B2 (en)	2005-12-20	2016-04-12	Bristol-Myers Squibb Company	Stable subcutaneous protein formulations and uses thereof
EA014232B1 (ru)	2005-12-20	2010-10-29	Бристол-Маерс Сквибб Компани	Стабильные белковые препараты
CA2647524C (en)	2006-04-05	2019-11-26	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007257692B2 (en) *	2006-06-12	2013-11-14	Aptevo Research And Development Llc	Single-chain multivalent binding proteins with effector function
NZ597334A (en) *	2006-09-13	2014-02-28	Abbott Lab	Cell culture improvements
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
AU2007317755A1 (en) *	2006-10-27	2008-05-15	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2924113B1 (de)	2007-03-02	2019-04-10	Wyeth LLC	Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
ES2688721T3 (es) *	2007-11-01	2018-11-06	Astellas Pharma Inc.	Polipéptidos y ácidos nucleicos inmunosupresores
PT2132228E (pt)	2008-04-11	2011-10-11	Emergent Product Dev Seattle	Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
CA2722173A1 (en)	2008-04-22	2009-10-29	The Rockefeller University	Methods of identifying anti-inflammatory compounds
US7915222B2 (en) *	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
MX2011004201A (es)	2008-10-20	2011-05-24	Abbott Lab	Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en)	2008-10-20	2016-12-08	Abbvie Inc.	Isolation and purification of antibodies using Protein A affinity chromatography
US9540426B2 (en)	2009-10-06	2017-01-10	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
US20110262965A1 (en) *	2010-04-23	2011-10-27	Life Technologies Corporation	Cell culture medium comprising small peptides
PL3330370T3 (pl)	2010-04-26	2021-09-20	Novartis Ag	Sposób hodowania komórek cho
EP2702077A2 (de) *	2011-04-27	2014-03-05	AbbVie Inc.	Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
CN103717729B (zh)	2011-07-08	2017-11-21	动量制药公司	细胞培养方法
WO2013114165A1 (en) *	2012-01-30	2013-08-08	Dr Reddy's Laboratories Limited	Process of obtaining glycoprotein composition with increased afucosylation content
WO2013114240A2 (en) *	2012-01-30	2013-08-08	Dr. Reddy's Laboratories Limited	Method for obtaining a glycoprotein composition
US10059770B2 (en)	2012-01-30	2018-08-28	Dr. Reddy's Laboratories Limited	Process of modulating man5 and/or afucosylation content of a glycoprotein composition
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
WO2013166339A1 (en)	2012-05-02	2013-11-07	Life Technologies Corporation	High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
DK2867251T3 (da)	2012-06-29	2019-11-25	Bristol Myers Squibb Co	Fremgangsmåder til reduktion af glycoproteinaggregering
US9664671B2 (en)	2012-07-24	2017-05-30	Nissan Chemical Industries, Ltd.	Culture medium composition and method of culturing cell or tissue using thereof
CN104781389B (zh) *	2012-08-23	2018-05-29	日产化学工业株式会社	蛋白质生产促进剂
US10017805B2 (en)	2012-08-23	2018-07-10	Nissan Chemical Industries, Ltd.	Enhancing ingredients for protein production from various cells
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
KR20150043523A (ko)	2012-09-02	2015-04-22	애브비 인코포레이티드	단백질 불균일성의 제어 방법
JP2015531244A (ja)	2012-10-15	2015-11-02	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	タンパク質を製造するための哺乳動物細胞培養方法
US20140106405A1 (en) *	2012-10-15	2014-04-17	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
TWI771890B (zh) *	2013-03-14	2022-07-21	美商安美基公司	用於增加重組蛋白質之甘露糖含量之方法
US8956830B2 (en)	2013-03-14	2015-02-17	Momenta Pharmaceuticals, Inc.	Methods of cell culture
WO2014151230A2 (en)	2013-03-15	2014-09-25	Bristol-Myers Squibb Company	Method of treating granulomatosis with polyangiitis
WO2014170866A2 (en) *	2013-04-18	2014-10-23	Dr. Reddy's Laboratories Limited	Process of obtaining glycoprotein composition with increased galactosylation content
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
TWI793159B (zh) *	2013-10-23	2023-02-21	美商健臻公司	重組醣蛋白及其用途
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
EP3683316A1 (de) *	2014-01-30	2020-07-22	Coherus Biosciences, Inc.	Perfusionsmedien
WO2015164595A1 (en)	2014-04-25	2015-10-29	Bristol-Myers Squibb Company	Use of ctla4 compound for achieving drug-free remission in subjects with early ra
EP3158077B1 (de) *	2014-06-18	2023-04-05	Medimmune, LLC	Zellkulturverfahren und medium mit n-acetylcystein
ES2719876T3 (es)	2014-10-15	2019-07-16	Alexion Pharma Inc	Métodos para replicar un cultivo celular de producción de eculizumab a gran escala
EP3072957B1 (de)	2015-03-23	2019-07-10	Lonza Ltd	Verfahren zur steuerung der proteinglycosylierung
HUE054616T2 (hu)	2015-04-17	2021-09-28	Alpine Immune Sciences Inc	Immunmodulátor fehérjék hangolható affinitásokkal
EP3322813A1 (de) *	2015-07-13	2018-05-23	Life Technologies Corporation	System und verfahren für verbesserte transiente proteinexpression in cho-zellen
EP3352760B1 (de)	2015-09-21	2026-03-11	Aptevo Research and Development LLC	Cd3-bindende polypeptide
CN108350416A (zh) *	2015-11-09	2018-07-31	百时美施贵宝公司	操纵在cho细胞中产生的多肽的品质属性的方法
EP3464608A4 (de) *	2016-06-02	2020-01-29	Klotho Therapeutics, Inc.	Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit
CA3041910A1 (en)	2016-11-22	2018-05-31	Klotho Therapeutics, Inc.	Novel recombinant klotho proteins and compositions and methods involving the same
WO2019074983A1 (en)	2017-10-10	2019-04-18	Alpine Immune Sciences, Inc.	CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
EP3735417A1 (de)	2018-01-03	2020-11-11	Alpine Immune Sciences, Inc.	Immunmodulatorische multidomänenproteine und verfahren zu deren verwendung
IL307155B2 (en)	2018-05-01	2025-11-01	Amgen Inc	Antibodies with modulated glycan profiles
CN111321188B (zh) *	2018-12-17	2024-10-29	嘉和生物药业有限公司	一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用
US11098311B2 (en)	2019-12-06	2021-08-24	Regeneron Pharmaceuticals, Inc.	Anti-VEGF protein compositions and methods for producing the same
CN113025648B (zh) *	2019-12-09	2023-06-02	广东菲鹏制药股份有限公司	Expi293细胞瞬时表达目标蛋白的方法及其应用
CN111676184B (zh) *	2020-05-15	2021-01-29	上海多宁生物科技有限公司	一种由补料培养基共混的基础培养基及其制备方法和应用
KR20230045615A (ko) *	2020-08-14	2023-04-04	브리스톨-마이어스 스큅 컴퍼니	단백질을 제조하는 방법
WO2022036275A2 (en) *	2020-08-14	2022-02-17	Bristol-Myers Squibb Company	Manufacturing process for protein
WO2022162700A1 (en) *	2021-02-01	2022-08-04	Dr. Reddy's Laboratories Limited	Cell culture methods
JP7589759B2 (ja)	2021-02-08	2024-11-26	株式会社島津製作所	推定装置
EP4634397A1 (de) *	2022-12-12	2025-10-22	Genentech Inc.	Optimierung des sialinsäuregehalts von polypeptiden
WO2025038362A1 (en)	2023-08-11	2025-02-20	Merck Sharp & Dohme Llc	Monovalent interleukin 12 (il-12) heterodimeric fc proteins

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4357422A (en)	1980-08-14	1982-11-02	Massachusetts Institute Of Technology	Method of enhancing interferon production
FR2543158B1 (fr) *	1983-03-24	1985-11-15	Inst Nat Sante Rech Med	Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4994387A (en)	1983-11-10	1991-02-19	The Wistar Institute	Process and medium for cloning and long-term serial cultivation of human endothelial cells
US5132223A (en)	1983-11-10	1992-07-21	Thomas Jefferson University	Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US5112749A (en) *	1987-10-02	1992-05-12	Praxis Biologics, Inc.	Vaccines for the malaria circumsporozoite protein
DE3801236A1 (de) *	1988-01-18	1989-07-27	Boehringer Mannheim Gmbh	Pentosansulfat-medium
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6685941B1 (en)	1988-11-23	2004-02-03	The Regents Of The University Of Michigan	Methods of treating autoimmune disease via CTLA-4Ig
US6905680B2 (en)	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
US5858358A (en)	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US6534055B1 (en)	1988-11-23	2003-03-18	Genetics Institute, Inc.	Methods for selectively stimulating proliferation of T cells
CA2003455C (en)	1988-11-23	2000-02-22	Craig B. Thompson	Immunotherapy involving cd28 stimulation
US5580756A (en)	1990-03-26	1996-12-03	Bristol-Myers Squibb Co.	B7Ig fusion protein
US7070776B1 (en)	1990-03-26	2006-07-04	Bristol-Myers Squibb Company	Methods for blocking binding of CD28 receptor to B7
GB9022545D0 (en) †	1990-10-17	1990-11-28	Wellcome Found	Culture medium
US5318898A (en)	1991-04-02	1994-06-07	Genetics Institute, Inc.	Production of recombinant bone-inducing proteins
TW318142B (de)	1991-06-03	1997-10-21	Mitsubishi Chemicals Co Ltd
US5844095A (en)	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
DE122007000078I2 (de)	1991-06-27	2011-01-13	Bristol Myers Squibb Co	CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en)	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69333580D1 (de)	1992-04-07	2004-09-09	Univ Michigan	Immunregulation über die cd28-route
US5773253A (en)	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
US5348877A (en)	1993-03-12	1994-09-20	Boyce Thompson Institute For Plant Research, Inc.	Method of adapting anchorage-dependent cell lines to suspension conditions
WO1994028912A1 (en)	1993-06-10	1994-12-22	The Regents Of The University Of Michigan	Cd28 pathway immunosuppression
SE9303601D0 (sv) *	1993-11-01	1993-11-01	Kabi Pharmacia Ab	Improved cell cultivation method and medium
CA2188165C (en) *	1994-04-28	2007-08-28	Marilyn Kehry	Methods for proliferating and differentiating b cells, and uses thereof
US6719972B1 (en)	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US6183971B1 (en) *	1995-03-24	2001-02-06	Takeda Chemical Industries, Ltd.	Human betacellulin-specific antibodies and uses thereof
US5721121A (en)	1995-06-06	1998-02-24	Genentech, Inc.	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en)	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
EP0842425A1 (de) *	1995-07-28	1998-05-20	Beth Israel Deaconess Medical Center, Inc.	Verfahren und testsatz für die mutagenese-testung
JP4306813B2 (ja) *	1995-09-19	2009-08-05	アスビオファーマ株式会社	動物細胞の新規培養方法
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5728580A (en) *	1996-02-20	1998-03-17	Cornell Research Foundation, Inc.	Methods and culture media for inducing single cell suspension in insect cell lines
US6043092A (en) *	1996-03-18	2000-03-28	University Of Pittsburgh	Cell culture media for mammalian cells
JP4751493B2 (ja)	1996-03-20	2011-08-17	ブリストル−マイヤーズスクイッブカンパニー	Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
US5856159A (en) *	1996-03-27	1999-01-05	Cytel Corporation	Production of galactosyltransferase
US5851800A (en)	1996-05-14	1998-12-22	Pharmacia & Upjohn Ab	Process for producing a protein
AU4330597A (en)	1996-08-30	1998-03-19	Life Technologies, Inc.	Serum-free mammalian cell culture medium, and uses thereof
ZA98533B (en)	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en)	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
DE59813187D1 (de) †	1997-12-03	2005-12-15	Roche Diagnostics Gmbh	Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
DE69929198T2 (de)	1998-05-29	2006-08-10	Genentech, Inc., South San Francisco	Zellkulturverfahren für die produktion von glycoproteinen
DE19852729A1 (de) *	1998-11-16	2000-05-18	Werner Reutter	Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
EP1131415A4 (de) *	1998-11-18	2002-09-11	Neose Technologies Inc	Kostengünstige herstellung von oligosacchariden
TR200504220T2 (tr)	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2000065070A2 (en)	1999-04-26	2000-11-02	Genentech, Inc.	Cell culture process for glycoproteins
DE60120356T2 (de)	2000-02-08	2007-06-14	Genentech, Inc., South San Francisco	Verbesserte galactosylierung von rekombinanten proteinen
WO2001059075A1 (en)	2000-02-08	2001-08-16	Genentech, Inc.	Improved sialylation of glycoproteins
HK1048126B (en)	2000-05-26	2005-03-04	Bristol-Myers Squibb Co.	Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
IL152316A0 (en)	2000-06-09	2003-05-29	Bristol Myers Squibb Co	Pharmaceutical compositions and kits for treating transplant rejection
KR100895552B1 (ko)	2000-07-03	2009-04-29	브리스톨-마이어스스퀴브컴파니	가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20020099183A1 (en) *	2000-08-23	2002-07-25	Pluschkell Stefanie Beate	Process for the preparation of neutrophil inhibitory factor
CA2436139A1 (en)	2001-01-26	2002-08-01	Emory University	Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en)	2001-05-23	2007-12-04	Bristol-Myers Squibb Company	Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
MXPA05000552A (es) †	2002-07-15	2005-04-28	Immunex Corp	Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
US6924124B1 (en) *	2002-08-23	2005-08-02	Immunex Corporation	Feeding strategies for cell culture
TWI312368B (en)	2002-12-23	2009-07-21	Bristol Myers Squibb Compan	Mammalian cell culture processes for protein production
MXPA05006522A (es) *	2002-12-23	2006-02-17	Bristol Myers Squibb Co	Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
KR20090087514A (ko)	2003-08-04	2009-08-17	브리스톨-마이어스 스큅 컴퍼니	가용성 ｃｔｌａ4 돌연변이체 분자를 사용한 심혈관 질환의 치료 방법
EP1979372A2 (de) *	2006-01-09	2008-10-15	Wyeth	Verfahren zur etikettierung vorübergehend exprimierter proteine in eukaryotischen massenzellkulturen

2003
- 2003-12-18 MX MXPA05006522A patent/MXPA05006522A/es active IP Right Grant
- 2003-12-18 KR KR1020057011764A patent/KR101088223B1/ko not_active Expired - Lifetime
- 2003-12-18 DK DK03808535.3T patent/DK1576182T4/da active
- 2003-12-18 WO PCT/US2003/040939 patent/WO2004058944A2/en not_active Ceased
- 2003-12-18 CN CNB2003801099353A patent/CN100402660C/zh not_active Expired - Lifetime
- 2003-12-18 CA CA2508925A patent/CA2508925C/en not_active Expired - Lifetime
- 2003-12-18 AT AT03808535T patent/ATE488600T1/de active
- 2003-12-18 ES ES03808535T patent/ES2354610T5/es not_active Expired - Lifetime
- 2003-12-18 EP EP03808535.3A patent/EP1576182B2/de not_active Expired - Lifetime
- 2003-12-18 PT PT03808535T patent/PT1576182E/pt unknown
- 2003-12-18 PL PL377603A patent/PL377603A1/pl not_active Application Discontinuation
- 2003-12-18 AU AU2003303394A patent/AU2003303394B2/en not_active Expired
- 2003-12-18 US US10/740,645 patent/US7332303B2/en not_active Expired - Lifetime
- 2003-12-18 SI SI200331927T patent/SI1576182T2/sl unknown
- 2003-12-18 DE DE60335024T patent/DE60335024D1/de not_active Expired - Lifetime
- 2003-12-18 JP JP2004563950A patent/JP4496086B2/ja not_active Expired - Lifetime
- 2003-12-18 TW TW092136006A patent/TWI328614B/zh not_active IP Right Cessation
- 2003-12-18 BR BR0316882-4A patent/BR0316882A/pt not_active IP Right Cessation
2005
- 2005-05-30 IL IL168873A patent/IL168873A/en active IP Right Grant
- 2005-06-22 CO CO05061313A patent/CO5590971A2/es not_active Application Discontinuation
2007
- 2007-10-22 US US11/975,799 patent/US20080070280A1/en not_active Abandoned
2011
- 2011-02-14 CY CY20111100184T patent/CY1111358T1/el unknown

Also Published As

Publication number	Publication date
JP2006511224A (ja)	2006-04-06
EP1576182A2 (de)	2005-09-21
US20050084933A1 (en)	2005-04-21
EP1576182B2 (de)	2020-01-15
WO2004058944A3 (en)	2004-09-10
MXPA05006522A (es)	2006-02-17
EP1576182A4 (de)	2007-05-02
US7332303B2 (en)	2008-02-19
ES2354610T5 (es)	2020-09-14
CA2508925C (en)	2012-08-28
BR0316882A (pt)	2005-10-25
EP1576182B1 (de)	2010-11-17
JP4496086B2 (ja)	2010-07-07
SI1576182T2 (sl)	2020-07-31
IL168873A (en)	2013-04-30
DK1576182T4 (da)	2020-04-20
CA2508925A1 (en)	2004-07-15
ES2354610T3 (es)	2011-03-16
CN100402660C (zh)	2008-07-16
CY1111358T1 (el)	2015-08-05
DK1576182T3 (da)	2011-02-21
WO2004058944A2 (en)	2004-07-15
AU2003303394B2 (en)	2009-02-19
CO5590971A2 (es)	2005-12-30
TW200504221A (en)	2005-02-01
US20080070280A1 (en)	2008-03-20
KR20050103466A (ko)	2005-10-31
TWI328614B (en)	2010-08-11
CN1820080A (zh)	2006-08-16
DE60335024D1 (de)	2010-12-30
AU2003303394A1 (en)	2004-07-22
WO2004058944A8 (en)	2005-07-21
PT1576182E (pt)	2011-01-21
SI1576182T1 (sl)	2011-01-31
PL377603A1 (pl)	2006-02-06
HK1075474A1 (en)	2005-12-16
KR101088223B1 (ko)	2011-11-30

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1576182

Country of ref document: EP

Publication	Publication Date	Title
ATE488600T1 (de)	2010-12-15	Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
TW200512297A (en)	2005-04-01	Mammalian cell culture processes for protein production
EA200501774A1 (ru)	2006-04-28	Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
Ljunggren et al.	1994	Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures
EA201490631A1 (ru)	2016-05-31	Способы культивирования клеток млекопитающих для получения белка
WO2002101019A3 (en)	2003-04-10	Methods of culturing animal cells and polypeptide production in animal cells
WO2005028626A3 (en)	2005-08-18	Cell culture media
NZ597742A (en)	2014-02-28	Method of producing a polypeptide or virus of interest in a continuous cell culture
NO20072719L (no)	2007-05-29	Serumfritt cellekulturmedium for pattedyrceller
IS8618A (is)	2007-03-06	Æti og rækt fósturstofnfrumna
WO2004090096A3 (en)	2005-03-03	Methods for neural differentiation of embryonic stem cells using protease passaging techniques
AR086200A1 (es)	2013-11-27	Hongos filamentosos que tienen un fenotipo de viscosidad alterado
ATE496117T1 (de)	2011-02-15	Hautregenerationssystem
GB2429211A (en)	2007-02-21	Feeder independent extended culture of embryonic stem cells
Xie et al.	2025	An overview of recent progress in cultured meat: Focusing on technology, quality properties, safety, industrialization, and public acceptance
NZ515762A (en)	2002-11-26	Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions
BRPI0517942A (pt)	2008-10-21	meio de cultura de células isento de soro para células de mamìferos
ATE292688T1 (de)	2005-04-15	Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
Li et al.	2009	Establishment and characterization of the fibroblast line from Silkie Bantam
RU2021127370A (ru)	2023-04-19	Линия клеток, содержащая новый маркер отбора, и ее применение для продуцирования белков
DE69923595D1 (de)	2005-03-10	Herstellung von proteinen
Cruz et al.	2002	Correlation between BHK Cell Specific Productivity and Metabolism
UA81564C2 (ru)	2008-01-10	Способ дифференциации стромальных столбовых клеток человека в культуральной среде in vitro